Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

9. maj 2014 opdateret af: Boehringer Ingelheim
The objective of this PMS study is the evaluation of depressive symptoms measured with Unified Parkinson's Disease Rating Scale (UPDRS) Part I (mentation, behavior and mood) and with Hospital Anxiety and Depression Scale Depression Subscore (HADS-D) under pramipexole treatment in early and advanced PD patients. In addition it will be investigated whether improvement of depressive symptoms is linked to improvement in motor function (UPDRS Part III). 250 patients diagnosed with Parkinson's disease (PD) will be investigated by 80 specialists (neurologists or neurologists/psychiatrists) across Austria. Pramipexole will be taken orally at an initial dosage of 0.375 mg/day (using a three times daily schedule independently of food intake) and can be titrated upwards, as required, at weekly intervals to a maximum total daily dose of 4,5 mg (TID) as per Summary of Product Characteristics (SPC).

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

286

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Amstetten, Østrig
        • Boehringer Ingelheim Investigational Site
      • Bad Hall, Østrig
        • Boehringer Ingelheim Investigational Site
      • Bad Ischl, Østrig
        • Boehringer Ingelheim Investigational Site
      • Bad Radkersburg, Østrig
        • Boehringer Ingelheim Investigational Site
      • Baden, Østrig
        • Boehringer Ingelheim Investigational Site
      • Bregenz, Østrig
        • Boehringer Ingelheim Investigational Site
      • Bruck an der Mur, Østrig
        • Boehringer Ingelheim Investigational Site
      • Deutschlandsberg, Østrig
        • Boehringer Ingelheim Investigational Site
      • Dornbirn, Østrig
        • Boehringer Ingelheim Investigational Site
      • Eisenstadt, Østrig
        • Boehringer Ingelheim Investigational Site
      • Feldkirch, Østrig
        • Boehringer Ingelheim Investigational Site
      • Feldkirchen, Østrig
        • Boehringer Ingelheim Investigational Site
      • Gmunden, Østrig
        • Boehringer Ingelheim Investigational Site
      • Graz, Østrig
        • Boehringer Ingelheim Investigational Site
      • Grieskirchen, Østrig
        • Boehringer Ingelheim Investigational Site
      • Gänserndorf, Østrig
        • Boehringer Ingelheim Investigational Site
      • Hall in Tirol, Østrig
        • Boehringer Ingelheim Investigational Site
      • Hallein, Østrig
        • Boehringer Ingelheim Investigational Site
      • Hermagor, Østrig
        • Boehringer Ingelheim Investigational Site
      • Hohenems, Østrig
        • Boehringer Ingelheim Investigational Site
      • Hollabrunn, Østrig
        • Boehringer Ingelheim Investigational Site
      • Horn, Østrig
        • Boehringer Ingelheim Investigational Site
      • Imst, Østrig
        • Boehringer Ingelheim Investigational Site
      • Innsbruck, Østrig
        • Boehringer Ingelheim Investigational Site
      • Judenburg, Østrig
        • Boehringer Ingelheim Investigational Site
      • Kapfenberg, Østrig
        • Boehringer Ingelheim Investigational Site
      • Klagenfurt, Østrig
        • Boehringer Ingelheim Investigational Site
      • Klosterneuburg, Østrig
        • Boehringer Ingelheim Investigational Site
      • Knittelfeld, Østrig
        • Boehringer Ingelheim Investigational Site
      • Krems, Østrig
        • Boehringer Ingelheim Investigational Site
      • Kufstein, Østrig
        • Boehringer Ingelheim Investigational Site
      • Leoben, Østrig
        • Boehringer Ingelheim Investigational Site
      • Lienz, Østrig
        • Boehringer Ingelheim Investigational Site
      • Lilienfeld, Østrig
        • Boehringer Ingelheim Investigational Site
      • Linz, Østrig
        • Boehringer Ingelheim Investigational Site
      • Melk, Østrig
        • Boehringer Ingelheim Investigational Site
      • Neunkirchen, Østrig
        • Boehringer Ingelheim Investigational Site
      • Oberwart, Østrig
        • Boehringer Ingelheim Investigational Site
      • Ried im Innkreis, Østrig
        • Boehringer Ingelheim Investigational Site
      • Salzburg, Østrig
        • Boehringer Ingelheim Investigational Site
      • Scheibbs, Østrig
        • Boehringer Ingelheim Investigational Site
      • Schwechat, Østrig
        • Boehringer Ingelheim Investigational Site
      • Spital an der Drau, Østrig
        • Boehringer Ingelheim Investigational Site
      • St. Johann im Pongau, Østrig
        • Boehringer Ingelheim Investigational Site
      • St. Pölten, Østrig
        • Boehringer Ingelheim Investigational Site
      • St. Veit an der Glan, Østrig
        • Boehringer Ingelheim Investigational Site
      • Stegersbach, Østrig
        • Boehringer Ingelheim Investigational Site
      • Stockerau, Østrig
        • Boehringer Ingelheim Investigational Site
      • Telfs, Østrig
        • Boehringer Ingelheim Investigational Site
      • Traun, Østrig
        • Boehringer Ingelheim Investigational Site
      • Villach, Østrig
        • Boehringer Ingelheim Investigational Site
      • Vöcklabruck, Østrig
        • Boehringer Ingelheim Investigational Site
      • W. Neustadt, Østrig
        • Boehringer Ingelheim Investigational Site
      • Wels, Østrig
        • Boehringer Ingelheim Investigational Site
      • Wien, Østrig
        • Boehringer Ingelheim Investigational Site
      • Wolfsberg, Østrig
        • Boehringer Ingelheim Investigational Site
      • Wörgl, Østrig
        • Boehringer Ingelheim Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

PD patients

Beskrivelse

Inclusion Criteria:

  • Idiopathic PD with or without fluctuations
  • Indication for treatment with Pramipexole
  • Presence of at least mild depressive symptoms (as judged by the treating physician)
  • Ability to reliably complete a self-rating scale (Hospital Anxiety and Depression Scale (HADS))

Exclusion Criteria:

  • Any contraindications according to the Summary of Product Characteristics (SPC), hypersensitivity to pramipexole or to any of the excipients
  • Ongoing treatment with pramipexole

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behaviour and Mood)
Tidsramme: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)

Rating scale scored from 0 (none) - 4 (severe). The UPDRS Part I (Mentation, Behaviour and Mood during the Past Week) consist of 4 items, each of them is scored from 0 (normal) to 4 (severe). Reduction in this score over time is interpreted as improvement.

Total UPDRS part I score ranges from 0 = best score to 16 = worst score

Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
Change From Baseline in Hospital Anxiety and Depression Scale - HADS-D Depression Subscore
Tidsramme: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)

Depression Scale - 7 items scored for each individual question from 0 = best and 3 = worst.

HADS is a self-assessment scale for the symptom severity of anxiety disorders and depression.

It comprises of 14 items, thereof seven statements describe anxiety and seven statements depression. Each answer is rated on a four-point scale (0-3). All seven answers are summarized and calculated to a total score to the anxiety scale and to the depression scale with a maximum score of 21 points for each scale.

Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
Change From Baseline in Hospital Anxiety and Depression Scale - HADS-A Anxiety Subscore
Tidsramme: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)

Anxiety Scale - 7 items scored for each individual question from 0 = best and 3 = worst.

HADS is a self-assessment scale for the symptom severity of anxiety disorders and depression.

It comprises of 14 items, thereof seven statements describe anxiety and seven statements depression. Each answer is rated on a four-point scale (0-3). All seven answers are summarized and calculated to a total score to the anxiety scale and to the depression scale with a maximum score of 21 points for each scale.

Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
Change From Baseline in UPDRS Part III (Motor Examination)
Tidsramme: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
14 components rating scale with 27 items scored by 0 (none) - 4 (severe)
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Primær færdiggørelse (Faktiske)

1. april 2008

Studieafslutning (Faktiske)

1. april 2008

Datoer for studieregistrering

Først indsendt

31. marts 2008

Først indsendt, der opfyldte QC-kriterier

1. april 2008

Først opslået (Skøn)

2. april 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

20. maj 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

9. maj 2014

Sidst verificeret

1. maj 2014

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner